Humacyte, Inc. HUMA

DURHAM, N.C., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the addition of life science industry veterans Scott Coward and Paul Kuznik to the Company’s Board of Directors, both of whom bring substantial experience in the areas of commercialization, enterprise leadership, and global operations. “We are delighted to welcome two

DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Founder, President, and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference in New York, NY on September 16, 2026, at 11:00am Eastern Time. Management will also b

– FDA authorizes extension of Symvess expiration dating from 18 months to 36 months – – Extended shelf life supported by additional stability data demonstrating Symvess continues to meet all established quality specifications throughout the 36-month dating period – DURHAM, N.C., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology company that develops bioengineered human tissues, today announced that the U.S. Food and Drug Administration (FDA) has a

– Supplemental Biologics License Application (BLA) expected to be filed with the Food and Drug Administration (FDA) in November 2026 – – Supplemental BLA will be supported by results from three Phase 3 studies of ATEV, including results from V012 dialysis access study in women – – The V012 dialysis access study found that women who received Humacyte's ATEV experienced an average of three more months without a dialysis catheter than women who received AV fistula, the current standard of care – DU

– Phase 3 results highlight benefits of ATEV for patients at higher risk of fistula failure, including all women and men with obesity and diabetes – – Publication provides peer-reviewed validation for V007 Phase 3 data, and complements recent release of Phase 3 V012 data showing ATEV outperformed standard of care for women on dialysis – DURHAM, N.C., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantab

– Jeromy Brink, MD, Mayo Clinic–trained vascular surgeon in Phoenix, is the first surgeon in Arizona to implant Symvess, the first and only FDA-approved bioengineered human blood vessel – – Symvess is available off-the-shelf in the operating room, sparing surgeons the time required to harvest a vein from a patient facing imminent limb loss – DURHAM, N.C., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology company that develops bioengineered human ti

Humacyte earnings update and stock context Humacyte (HUMA) reported second quarter 2026 results that included revenue of US$0.406 million and a net loss of US$36.8 million, alongside recent Nasdaq compliance pressure after its share price stayed below US$1.00. For the first half of 2026, the company reported revenue of US$0.901 million and a net loss of US$54.42 million. Earnings per share moved from a small profit a year ago to a basic loss of US$0.25 from continuing operations. Humacyte...

Humacyte stock has had a very rough run over the last several years, and current valuation checks now lean toward the shares looking expensive rather than like a clear bargain. Humacyte has declined 93.3% over the past 5 years, which puts recent pricing in the context of a very long and deep drawdown for existing shareholders. Recent progress in tissue engineered vessel programs and regulatory milestones may support expectations for future revenue, while the risk that clinical or regulatory...

Humacyte (NasdaqGS:HUMA) reported Phase 3 dialysis access data showing its acellular tissue engineered vessel outperformed standard of care for female patients. The company plans to file a supplemental Biologics License Application based on the female cohort results from the dialysis access trial. The FDA accepted an Investigational New Drug application for Humacyte’s new coronary vessel candidate, allowing clinical development to proceed. This progress at Humacyte is part of a wider push...

Despite a slow commercial quarter, the company's positive Phase III dialysis data and upcoming sBLA submission position it for significant growth in 2027.

Moby summary of Humacyte, Inc.'s Q2 2026 earnings call

Humacyte, Inc. (HUMA) delivered earnings and revenue surprises of -60.00% and -70.79%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?